Anavex Life Sciences Corp. Culture Company

Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA. has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and served as its Chief Financial Officer, Secretary and Treasurer since July 05, 2013. Dr. Missling serves as the Chief Financial Officer of SEE ALGAE Technology GmbH. He serves as a Secretary of Anavex Life Sciences Corp. Dr. Missling is a Partner of New York based investment bank Brimberg & Co and has over 15 years of finance experience. He is an Investment Banker at Deutsche Bank, serving companies across various industries. Dr. Missling served as Senior Vice President of Finance, Treasurer and Secretary of Asahi Kasei Pharma America Corporation (Previously known as Artisan Pharma, Inc.) Dr. Missling has extensive financial management, operational and strategic experience in the biotechnology and pharmaceutical industries. Dr. Missling served as the Chief Financial Officer of ImmunoGen Inc., from October 25, 2004 to January 2005 and also served as its Vice President of Finance and Treasurer. He also served as the Chief Financial Officer, Senior Vice President of Finance, Treasurer and Secretary of Curis, Inc. from August 2002 to November 2003 and Senior Vice President of Strategic Analysis and Planning from November 2003. Dr. Missling served as Chief Financial Officer of Axaron Bioscience AG from November 2001 to August 2002. From October 2001 to January 2002, Dr. Missling served as Head of Financial Planning of Aventis SA, with responsibility for financial modeling and determining investment valuations. From July 1997 to December 1999, he served as Head of Financial Planning at Hoechst AG. Dr. Missling was with Deutsche Bank in corporate finance and investment banking serving pharmaceutical, biotech and diagnostic companies. He served as an Analyst in the pharmaceutical /healthcare investment banking group of Deutsche Morgan Grenfell. He serves as a Member of Scientific Advisory Board at Anavex Life Sciences Corp. Dr. Missling serves as the Chairman at Anavex Life Sciences Corp. and has been its Director since July 5, 2013. Dr. Missling received his MBA from the Kellogg Graduate School of Management at WHU and Northwestern University, with a focus on partnership valuations in the Biotechnology and Pharmaceutical industries and his Ph.D., in Chemistry, summa cum laude and MSc from Ludwig-Maximilians-University in Munich.

Dr. Ulrich Elben, Ph.D. has been Vice President of Preclinical Operations at Anavex Life Sciences Corp. since December 2, 2015. Dr. Elben oversees the pipeline development and optimization. He served as Executive Officer of Halloran Consulting Group, Inc. Dr. Elben has more than 20 years of clinical development management experience in both biotech and biopharmaceutical companies. He also served as its Vice President of Program Management and Regulatory Operations at Halloran Consulting Group, Inc. He served as Chief Development Officer at Avaant Pharmaceuticals. Dr. Elben served as Vice President for Strategic Development Operations at Vertex Pharmaceuticals. Dr. Elben served as President and Chief Executive Officer of Axxima Pharmaceuticals AG since October 5, 2000. Dr. Elben joined Axxima Pharmaceuticals AG in January 2000 as the Vice President of Drug Development. He worked at Sanofi-Aventis. He is a chemist by education. He joined Hoechst as a Scientist in 1980 and became group leader in Medicinal Chemistry. In 1986, he was the Head of a research team for peripheral and cerebrovascular diseases. Since 1992, Dr. Elben has been working as the Project Director for world-wide pre-clinical and clinical drug development projects at HMR. He is a member of several organizations, including the CEO advisory board of the Florida Institute for the Commercialization of Public Research, BioFlorida and the Drug Information Association. Dr. Elben received a PhD in organic chemistry from the University Bonn.

Dr. Emmanuel O. Fadiran, also known as Tayo, RPh, PhD serves as Senior Vice President of Regulatory Affairs at Anavex Life Sciences Corp. Dr. Fadiran has over 26 years of experience in government service, of which 24 years were dedicated to the Food and Drug Administration (FDA). Prior to Anavex, Dr. Fadiran served as Clinical Pharmacology Team Leader at the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). Dr. Fadiran has been involved in the formulation of significant strategic FDA regulatory initiatives including serving as a member of the Senior Management Teams for the Data Standard (Janus) and Sentinel Initiatives. He was an active member of the FDA Senior Science Council working group for the creation and launching of the FDA's Strategic Plan for Regulatory Science in 2012. Recently, he has played an active role in the development of the Comprehensive in vitro Proarrhythmia Assay (CiPA) for future replacement of the thorough QT studies. As a long-term member of the FDA Institutional Review Board (IRB) he actively contributed to the development of standard operating procedures (SOP) for the committee. During his 24 years from 1993 to 2017 tenure at the FDA, he reviewed hundreds of NDAs, sNDAs, BLAs, ANDAs and INDs for approval and strategic recommendations for the development of several products across many therapeutic categories. He was also on review teams for several novel therapies including first in class approvals. Dr. Fadiran also led a cross-disciplinary NDA review team and authored the first Cross-Discipline Team Leader (CDTL) review for the Division of the Pulmonary & Allergy Products, Office of Drug Evaluation II, CDER. He was actively involved in the writing, internal/external training and the implementation of the US FDA Guidance for Industry for population pharmacokinetics. Dr. Fadiran is a recipient of the prestigious Fogarty International Fellowship of the National Institutes of Health (NIH) as well as numerous awards from the FDA, among them the Commissioner's Award of Excellence, in recognition of his outstanding contributions to regulatory review of applications and development of regulatory guidance and policies. Dr. Fadiran holds a BS (Pharmacy) and MS from Obafemi Awolowo University, Ile-Ife, Nigeria and a PhD in Pharmaceutical Sciences from the University of Strathclyde, Glasgow, UK.

Dr. Tasos Zografidis, PhD, has been the Vice President of Clinical Operations at Anavex Life Sciences Corp. since August 2014. Dr. Zografidis is responsible for managing its clinical programs, including the upcoming Phase 2a clinical trial for ANAVEX 2-73 and ANAVEX PLUS, its lead drug candidate combination in Alzheimer's disease. He has more than 25 years of experience in the pharmaceutical and healthcare industry, including 12 years at Wyeth (now Pfizer) in clinical project management He served as clinical and pharmaceutical consultant. He is involved in more than a dozen clinical trials and has co-authored numerous publications. At Wyeth, he spearheaded population pharmacokinetics analysis and its implementation in the clinical setting and positively differentiated compounds. His work resulted in increased sales and he received several clinical awards for his accomplishments. Dr. Zografidis first joined Wyeth in 1998 as a Product Manager. During his tenure until 2010, he had responsibility as Medical Liaison for the transplantation, haemophilia and oncology divisions where he was instrumental in driving sales in assigned European territories.

Dr. Alexandre Vamvakides, PhD, was a Scientific Founder of Anavex Life Sciences Corp. Dr. Vamvakides served as the Chief Scientific Officer of Anavex Life Sciences Corp. since January 31, 2007. Dr. Vamvakides served as Research Associate of Acron Genomics Inc. Dr. Vamvakides has over 36 years of experience in the public and institutional sector for research and synthesis of prototype molecules of nootropes, anti-neurodegenerative (anti-Alzheimer), anti-epileptic, anti-depression prototype molecules. In the past 30 years, Dr. Vamvakides has pioneered his expertise at the Institut National de la Sante et de la Recherche Medicale (INSERM) in Paris France, at the University of Athens (Greece) as well as at Chropi Pharmaceuticals (Piraeus, Greece), Ciba-Geigy (Basel, Switzerland) and Sanofi (Montpellier, France) for the development of new concepts in the aforementioned therapeutic/pharmacological areas. Dr. Vamvakides served as the Chairman of Scientific Advisory Board at Anavex Life Sciences Corp. since May 2008. Dr. Vamvakides served as an Executive Director of Anavex Life Sciences Corp. since January 31, 2007 to May 20, 2008. Dr. Vamvakides served as a Director of Acron Genomics Inc. since May 28, 2004. He is the author of more than 80 publications and abstracts, 60 of which are mentioned in 'Medicine', 'Chem. Abstracts' and 'Pascal'. Furthermore, Dr. Vamvakides has been granted more than 10 international patents regarding prototype molecules. He was appointed by the French Ministry of Education and is a Frequent Lecturer on Molecular Pharmacology at many of the Universities in France. During his career, he has been published over 80 times in highly respected Medical/Scientific journals. Dr. Vamvakides holds an MSc Chemistry from Bordeaux University, MSc in Pharmacology (Maitrise de Pharmacologie) from Medical School, University of Paris, MSc in Biochemistry (D.E.A. de Biochimie) from University of Paris and a PhD in Molecular Pharmacology (Doctorat de 3e Cycle en Pharmacologie Moleculaire) from University of Paris (University VI, Pierre & Marie Curie).